MX2023014679A - Peptidos grapados y metodos para su obtencion. - Google Patents

Peptidos grapados y metodos para su obtencion.

Info

Publication number
MX2023014679A
MX2023014679A MX2023014679A MX2023014679A MX2023014679A MX 2023014679 A MX2023014679 A MX 2023014679A MX 2023014679 A MX2023014679 A MX 2023014679A MX 2023014679 A MX2023014679 A MX 2023014679A MX 2023014679 A MX2023014679 A MX 2023014679A
Authority
MX
Mexico
Prior art keywords
present disclosure
disclosure provides
catenin
beta
agents
Prior art date
Application number
MX2023014679A
Other languages
English (en)
Spanish (es)
Inventor
Gregory L Verdine
John Hanney Mcgee
Brian Halbert White
Yaguang Si
Martin Robert Tremblay
Lorenzo Josue Alfaro-Lopez
Sarah Isabelle Cappucci
Zhi Li
Daniel Seungduk La
Paula Cristina Ortet
Kevin Ling
Peicheng Du
Jonathan Barry Hurov
Original Assignee
Fog Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fog Pharmaceuticals Inc filed Critical Fog Pharmaceuticals Inc
Publication of MX2023014679A publication Critical patent/MX2023014679A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2023014679A 2021-06-08 2022-06-08 Peptidos grapados y metodos para su obtencion. MX2023014679A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163208487P 2021-06-08 2021-06-08
US202163224834P 2021-07-22 2021-07-22
US202263303952P 2022-01-27 2022-01-27
PCT/US2022/032738 WO2022261257A1 (en) 2021-06-08 2022-06-08 Stapled peptides and methods thereof

Publications (1)

Publication Number Publication Date
MX2023014679A true MX2023014679A (es) 2024-01-15

Family

ID=84425507

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014679A MX2023014679A (es) 2021-06-08 2022-06-08 Peptidos grapados y metodos para su obtencion.

Country Status (9)

Country Link
US (1) US20240360179A1 (https=)
EP (1) EP4355350A4 (https=)
JP (1) JP2024522368A (https=)
KR (1) KR20240031957A (https=)
BR (1) BR112023025528A2 (https=)
CA (1) CA3218824A1 (https=)
IL (1) IL308790A (https=)
MX (1) MX2023014679A (https=)
WO (1) WO2022261257A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018329956A1 (en) 2017-09-07 2020-08-20 Fog Pharmaceuticals, Inc. Agents modulating beta-catenin functions and methods thereof
MX2021001943A (es) 2018-08-20 2021-07-15 Fog Pharmaceuticals Inc Colecciones de péptidos, agentes peptídicos y métodos de uso de los mismos.
WO2024130217A1 (en) * 2022-12-15 2024-06-20 Fog Pharmaceuticals, Inc. Stapled peptides and methods thereof
CN120529912A (zh) * 2022-12-15 2025-08-22 帕拉比利斯药物公司 订书钉化肽及其方法
WO2024130224A2 (en) * 2022-12-16 2024-06-20 Purdue Research Foundation Stapled peptides for sensitization of cancer to treatment
KR20260035134A (ko) * 2023-06-06 2026-03-12 파라빌리스 메디슨즈 인코포레이티드 스테이플화 펩티드 및 이의 방법
WO2025265097A1 (en) * 2024-06-20 2025-12-26 Parabilis Medicines, Inc. Stapled peptides and methods thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3549951A3 (en) * 2008-12-09 2019-11-20 Dana Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
WO2012040459A2 (en) * 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
EP3391898A3 (en) * 2013-03-13 2019-02-13 President and Fellows of Harvard College Stapled and stitched polypeptides and uses thereof
WO2016085280A1 (ko) * 2014-11-28 2016-06-02 서울대학교산학협력단 세포 투과성 스테이플 펩타이드, 이의 제조방법 및 그 용도
US10011631B2 (en) * 2015-12-01 2018-07-03 The University Of Hong Kong Stapled helical peptides and methods of synthesis
AU2018329956A1 (en) * 2017-09-07 2020-08-20 Fog Pharmaceuticals, Inc. Agents modulating beta-catenin functions and methods thereof
CN117567639A (zh) * 2017-10-27 2024-02-20 俄亥俄州国家创新基金会 用于细胞内递送装订肽的多肽缀合物
MX2021001943A (es) * 2018-08-20 2021-07-15 Fog Pharmaceuticals Inc Colecciones de péptidos, agentes peptídicos y métodos de uso de los mismos.
AU2021314310A1 (en) * 2020-07-22 2023-03-16 Fog Pharmaceuticals, Inc. Stapled peptides and methods thereof

Also Published As

Publication number Publication date
CA3218824A1 (en) 2022-12-15
US20240360179A1 (en) 2024-10-31
KR20240031957A (ko) 2024-03-08
IL308790A (en) 2024-01-01
BR112023025528A2 (pt) 2024-02-27
EP4355350A1 (en) 2024-04-24
WO2022261257A1 (en) 2022-12-15
JP2024522368A (ja) 2024-06-18
EP4355350A4 (en) 2025-10-01

Similar Documents

Publication Publication Date Title
MX2023014679A (es) Peptidos grapados y metodos para su obtencion.
CL2021000909A1 (es) Anticuerpos estabilizadores de trem2
DOP2025000112A (es) Compuestos moduladores de glp-1r
CO2021007993A2 (es) Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina
UY38685A (es) Moduladores de la vía de tensión integrada
CL2019002542A1 (es) Nuevas moléculas de unión a antígeno biespecíficas capaces de unirse específicamente a cd40 y a fap.
MX2023000947A (es) Peptidos grapados y metodos para su obtencion.
ECSP21026021A (es) Moduladores de la expresión de pnpla3
AR071510A1 (es) Anticuerpos anti- factor d humanizados y sus usos
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
CO2023015915A2 (es) Anticuerpos anti-ccr8
CL2023002907A1 (es) Anticuerpos anti-nectina-4 y usos de los mismos
MX2020002435A (es) Agentes que modulan las funciones de beta-catenina y sus métodos.
CL2020003008A1 (es) Estimulador de treg selectivo rur20kd-il-2 y composiciones relacionadas
BR112021021645A2 (pt) Anticorpos anti-hvem e uso dos mesmos.
BR112019003816A2 (pt) composição de tratamento de enxágue dos cabelos, método para tratamento de cabelos quimicamente danificados e uso de uma composição
CO2020008769A2 (es) Moduladores de la expresión dnm2
CL2023001735A1 (es) Moléculas bifuncionales novedosas para la degradación de proteínas dirigidas
CL2022001130A1 (es) Moléculas de fusión del ecd de siglec-9 y métodos de uso de estas
BR112022008287A2 (pt) Métodos de tratamento usando um modulador de mtorc1
AR048135A1 (es) Uso de gen de amiloide a serico en el diagnostico y tratamiento del glaucoma y en la identificacion de agentes anti-glaucoma.
BR112019003915A2 (pt) composição para tratamento dos cabelos, método de tratamento de cabelo danificado quimicamente e usos de uma composição
CO2021007006A2 (es) Moduladores de la expresión de irf5
CO2025016192A2 (es) Moléculas y métodos de uso de estas
AR115617A1 (es) Composición cosmética para el tratamiento de las fibras de queratina